TATasiu Hassan Aliyu

Tasiu Hassan Aliyu

*This is an algorithmically generated author record based on publicly available information.

Tasiu Hassan Aliyu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Structure based virtual screening of natural phytochemicals to identify potential CDK6 inhibitors for possible therapeutic intervention in acute myeloid leukemia

    by Tasiu Hassan Aliyu, Mandeep Chouhan, Richa Mishra, Prashant Kumar Tiwari, Shiv Kumar Verma, Abdulmunafi Salisu Umar, Mukesh Kumar, Sanjay Kumar

    Acute myeloid leukemia is one of the most prominent forms of acute leukemia in adults, which account for 32% of the overall incidents of adult leukemia, AML is a leukemia of bone marrow and blood characterized by uncontrolled proliferation of myeloid cells. CDK6 protein plays a crucial role in the regulation of cell cycle by forming complexes with cyclin D1, D2, D3 ensuring transition of cell cycle from D1 to S phase, this study focuses on identify the potential inhibitors of CDK6 protein for the management of AML. In silico approach was employed to identify the potential CDK6 protein inhibitors from natural compounds for the management of AML. 6,996 natural phytochemical compounds were screened, the top five compounds, were selected with the docking score ranging from −11.8 to −10.2 kcal/mol, which is better than the reference compound (−9.6 kcal/mol). Molecular dynamic simulations were performed for the top five chosen natural phytochemical compounds, i,e., Serpentinine, Strychnochrysine, Licoagrone, Tovophyllin B, and Isopsoralidin to further assess their stability and intermolecular interaction and they all displayed a good interaction with target protein. MM/GBSA was utilized to calculate free binding energy, in which all compounds showed reasonable stability (−80.06 to −41.52). Furthermore, ADME analysis demonstrated drug-likeness and pharmacokinetics properties of the chosen compounds. Hence these natural phytochemical compounds as potential inhibitors of CDK6 protein could be used for the management of AML.